AbbVie Inc. filed a Form 8-K with the SEC on September 3, 2026, disclosing under Item 7.01 (Regulation FD) the completion of its acquisition of Apogee Therapeutics, Inc., as announced in an attached press release dated the same day.

Key Highlights

  • Acquisition completed: AbbVie disclosed the completion of its acquisition of Apogee Therapeutics, Inc. on September 3, 2026.
  • Pipeline assets named: The filing identifies zumilokibart (APG777) and APG273 as acquired in-process research and development assets.
  • EPS guidance referenced: The filing notes that AbbVie's 2026 full-year and third-quarter adjusted diluted EPS guidance is among the forward-looking statements included in the disclosure.
  • Signed by CFO: The filing was signed by Scott T. Reents, Executive Vice President and Chief Financial Officer of AbbVie Inc.
  • Common stock listed on NYSE: AbbVie common stock ($0.01 par value) trades on the New York Stock Exchange under the symbol ABBV (NYSE:ABBV).

AbbVie's Apogee Therapeutics Acquisition: Key Details From the 8-K

AbbVie Inc. (NYSE:ABBV) filed a current report on Form 8-K on September 3, 2026, reporting under Item 7.01 (Regulation FD Disclosure) that it had completed its acquisition of Apogee Therapeutics, Inc. According to the filing, a press release announcing the completion was issued the same day and attached as Exhibit 99.1. The filing notes that the Item 7.01 disclosure, including the exhibit, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934."

The filing identifies two pipeline assets acquired through the transaction: zumilokibart (APG777) and APG273. The company's forward-looking statements, which are the company's own and subject to its stated cautionary language, address the anticipated benefits and integration of Apogee's operations, employees, and pipeline, as well as the expected impact on AbbVie's adjusted diluted earnings per share and the development and commercial potential of the acquired pipeline assets.

The filing also enumerates a range of risks associated with the acquisition, including integration challenges, the possibility that pipeline assets may not demonstrate anticipated clinical success, unknown or contingent liabilities assumed in connection with the transaction, and broader macroeconomic factors. AbbVie stated it "undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law."

What Was Disclosed

AbbVie's September 3, 2026 Form 8-K disclosed, under Regulation FD, the completion of its acquisition of Apogee Therapeutics, Inc. The filing attached a press release as Exhibit 99.1 and included forward-looking statements with accompanying risk factors related to the transaction.